Quick Answer
SELLAS Life Sciences Group, Inc. reported Operating Income of -$28.27 million for fiscal year 2025.
SELLAS Life Sciences Group, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$28.27M | +10.3% |
| 2024 | -$31.51M | +16.8% |
| 2023 | -$37.87M | +9.7% |
| 2022 | -$41.95M | -65.8% |
| 2021 | -$25.29M | -48.9% |
| 2020 | -$16.98M | +15.3% |
| 2019 | -$20.04M | +13.0% |
| 2017 | -$23.04M | -44.1% |
| 2016 | -$15.99M | +53.3% |
| 2015 | -$34.22M | +22.1% |
| 2014 | -$43.90M | -54.1% |
| 2013 | -$28.49M | -34.4% |
| 2012 | -$21.20M | -69.8% |
| 2011 | -$12.49M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.08M | +3.4% | -3.1% |
| June 30, 2025 | -$6.87M | +9.8% | -13.4% |
| March 31, 2025 | -$6.06M | +37.1% | +17.3% |
| September 30, 2024 | -$7.33M | +21.7% | +3.8% |
| June 30, 2024 | -$7.62M | +15.8% | +21.0% |
| March 31, 2024 | -$9.64M | +14.5% | -3.0% |
| September 30, 2023 | -$9.36M | -31.0% | -3.4% |
| June 30, 2023 | -$9.05M | -5.0% | +19.8% |
- SELLAS Life Sciences Group, Inc. showed an increase of +10.3% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, SELLAS Life Sciences Group, Inc.’s operating income has declined by 126.4% (from -$12.49 million to -$28.27 million).
- The most recent figure is from SELLAS Life Sciences Group, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: